<HTML lang="en" dir="ltr" class="client-nojs">
<style type="text/css">
A:before { content:' '; } 
A:after { content:' '; } 
SPAN:before { content:' '; } 
SPAN:after { content:' '; } 
</style>
<BODY class="mediawiki ltr sitedir-ltr ns-0 ns-subject page-Team_TP-CC_San_Diego_Results skin-igem action-view"><DIV id="globalWrapper"><DIV id="content" class="mw-body" role="main"><DIV id="top_title"><H1 id="firstHeading" class="firstHeading"><SPAN dir="auto">Team:TP-CC San Diego/Results</SPAN></H1></DIV><DIV id="HQ_page"><DIV id="bodyContent"><DIV id="mw-content-text" lang="en" dir="ltr" class="mw-content-ltr"><DIV id="navbar"><DIV id="navbar-fill"><DIV class="dropdown nav-animation"><BUTTON class="dropbtn" class="" id="title" style="color: white"><A href="https://2017.igem.org/Team:TP-CC_San_Diego"> Home </A></BUTTON></DIV><DIV class="dropdown"><BUTTON class="dropbtn"> Project </BUTTON><DIV class="dropdown-content" style="left:0;"><A style="font-family: 'Montserrat', sans-serif;" href="https://2017.igem.org/Team:TP-CC_San_Diego/Description">Description</A><A style="font-family: 'Montserrat', sans-serif;" href="https://2017.igem.org/Team:TP-CC_San_Diego/Results">Results</A><A style="font-family: 'Montserrat', sans-serif;" href="https://2017.igem.org/Team:TP-CC_San_Diego/Model">Modeling</A></DIV></DIV><DIV class="dropdown"><BUTTON class="dropbtn"> Notebook </BUTTON><DIV class="dropdown-content"><A style="font-family: 'Montserrat', sans-serif;" href="https://2017.igem.org/Team:TP-CC_San_Diego/LabBook">Lab Notebook</A><A style="font-family: 'Montserrat', sans-serif;" href="https://2017.igem.org/Team:TP-CC_San_Diego/InterLab">Interlab Study</A><A style="font-family: 'Montserrat', sans-serif;" href="https://2017.igem.org/Team:TP-CC_San_Diego/Protocols">Protocols</A><A style="font-family: 'Montserrat', sans-serif;" href="https://2017.igem.org/Team:TP-CC_San_Diego/MedalCriteria">Medal Criteria</A></DIV></DIV><DIV class="dropdown"><BUTTON class="dropbtn"> Human Practices </BUTTON><DIV class="dropdown-content"><A style="font-family: 'Montserrat', sans-serif;" href="https://2017.igem.org/Team:TP-CC_San_Diego/HP/Silver">Human Practices</A><A style="font-family: 'Montserrat', sans-serif;" href="https://2017.igem.org/Team:TP-CC_San_Diego/HP/Gold_Integrated">Integrated Practices</A><A style="font-family: 'Montserrat', sans-serif;" href="https://2017.igem.org/Team:TP-CC_San_Diego/Collaborations">Collaborations</A></DIV></DIV><DIV class="dropdown"><BUTTON class="dropbtn"> Team </BUTTON><DIV class="dropdown-content"><A style="font-family: 'Montserrat', sans-serif;" href="https://2017.igem.org/Team:TP-CC_San_Diego/Team">Team</A><A style="font-family: 'Montserrat', sans-serif;" href="https://2017.igem.org/Team:TP-CC_San_Diego/Attributions">Attributions</A></DIV></DIV></DIV></DIV><H2 class="main-title fade-in"> Results </H2><DIV class="text-wrapper"><H3 class="day"> Effects of ecDNA </H3><P style="padding: 2% 11%;font-size:16px;">There is a significantly depressed rate of cell growth due to the treatment. New cell growth, measured in the increased of density, was significantly retarded in the induced group. Based on the single factor analysis of variance test, our data after testing declares a p-value deemed low enough to reject the null hypothesis.</P><H3 class="day">Parts</H3><DIV class="rowfirst"><DIV class="item1"><SPAN class="caption">BBa_K2369000</SPAN></DIV><DIV class="item2"><SPAN class="caption">BBa_K2369001</SPAN></DIV><DIV class="item3"><SPAN class="caption">BBa_K2369002</SPAN></DIV></DIV><H3 class="day">Images</H3><H3 class="text-title"> EGFR Testing </H3><CENTER><DIV class="containertop2"><DIV class="item"><SPAN class="caption"> EGFR vs. Normalized Vector Expansion</SPAN></DIV><DIV class="item"><SPAN class="caption"> E1G4</SPAN></DIV></DIV></CENTER><H3 class="text-title"> References </H3><CENTER><DIV class="containertop2"><DIV class="item"><SPAN class="caption"> Guide RNA plasmid design  </SPAN></DIV><DIV class="item"><SPAN class="caption"> 100 Basepair ladder</SPAN></DIV></DIV></CENTER><H3 class="text-title">guide RNAs </H3><CENTER><DIV class="containertop"><DIV class="item"><SPAN class="caption"> E1G2</SPAN></DIV><DIV class="item"><SPAN class="caption"> E1G4</SPAN></DIV><DIV class="item"><SPAN class="caption"> E8G2</SPAN></DIV><DIV class="item"><SPAN class="caption"> E8G3 </SPAN></DIV></DIV></CENTER><H3 class="text-title"> Gels </H3><CENTER><DIV class="containertop3"><DIV class="item"><SPAN class="caption"> Digested TLCV2 Vector </SPAN></DIV><DIV class="item"><SPAN class="caption"> PCR </SPAN></DIV><DIV class="item"><SPAN class="caption"> GBM39 Genomic DNA </SPAN></DIV></DIV></CENTER><H3 class="day">Summary</H3><P style="padding: 0 11% 4% 11%;font-size: 16px;">
We were able to confirm that the GBM39 cell line had a substantial copy number of the EGFR gene. From there, we designed 4 guide RNAs. Two from exon 1 and two from exon 8. We were unable to design any gRNA using exons 2-7 because in the GBM-39 cell line, that portion of the EGFR gene is mutated. Using the TLCV2 backbone, we removed the stuffer sequence and inserted the guideRNAs in its place.  We were successful with constructing 3 gRNAs but the 4th failed to clone twice. After Sequencing our plasmids, we transfected the guideRNAs into GBM39 cells. Currently, we are monitoring the growth of the cells, and confluency and growth of the cancerous cells has been, over the past 2 months, negatively affected in a statistically significant manner - with over a reduction in total confluency growth of over 50% when compared to the control, suggesting that our treatment has an inhibitory effect upon cancer cell growth.
</P></DIV></DIV></DIV></DIV></DIV></DIV></BODY></HTML>